Diabetes complications

The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The chronic kidney disease (CKD)‐REIN cohort study

Diabetes Obes MetabPublished Prospective cohort study

Main finding · Cardiorenal eventsResult — go to the resultHazard ratio 0.70 95% CI 0.57–0.85

Authors' conclusion

These findings suggest that the attainment of a combination of nephroprotection targets is associated with better cardiorenal outcomes and a lower mortality rate in people with diabetic kidney disease.

Study context

Population
Patients with diabetes and CKD stages 3–4 (eGFR 15–60 ml/min/1.73 m²), French CKD-REIN cohort; 69% men, mean age 70 ± 10 years, eGFR 33 ± 11 ml/min/1.73 m²
Participants
1,260 patients
Exposure
Attainment of two nephroprotection targets vs zero or one target
Outcome
Cardiorenal events
Follow-up
Median 4.9 years
Methodological detailsadjusted Cox regression
  • Adjusted Cox regression

Main finding

As reported in the abstract

Hazard ratio

0.70

95% CI 0.57–0.85

Two targetsvs Zero or one target
HR 0.70 (95% CI 0.57–0.85)

Observational data: associations, not effects.

Further findings

OutcomeHR (CI)
Incident kidney failure with replacement therapyAdjusted0.58 (0.43–0.77)
4-point MACE (CV death, MI, stroke, hospitalization for HF)Adjusted0.75 (0.57–0.99)
All-cause mortalityAdjusted0.59 (0.42–0.82)

Subgroup urinary albumin-creatinine ratio ≥300 mg/g: at least two targets vs no targets

Cardiorenal events, HR (at least two vs zero targets)
0.61 (0.39-0.96)
4-point MACE, HR
0.53 (0.28-0.98)
All-cause mortality, HR
0.35 (0.17-0.70)

Original publication

The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD‐REIN cohort study. Diabetes Obes Metab. Published 28 February 2024. doi:10.1111/dom.15507

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.